BidaskClub upgraded shares of IDEXX Laboratories (NASDAQ:IDXX) from a buy rating to a strong-buy rating in a report released on Wednesday.
Other equities research analysts have also issued reports about the stock. Canaccord Genuity reiterated a buy rating and set a $210.00 target price on shares of IDEXX Laboratories in a research note on Monday, January 29th. Bank of America boosted their target price on shares of IDEXX Laboratories from $200.00 to $220.00 and gave the company a buy rating in a research note on Friday, February 2nd. Zacks Investment Research lowered shares of IDEXX Laboratories from a buy rating to a hold rating in a research note on Wednesday, January 31st. Piper Jaffray Companies boosted their target price on shares of IDEXX Laboratories to $211.00 and gave the company an overweight rating in a research note on Thursday, February 1st. Finally, Aegis reiterated a sell rating on shares of IDEXX Laboratories in a research note on Friday, December 8th. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $194.00.
IDEXX Laboratories (IDXX) traded up $5.72 during mid-day trading on Wednesday, reaching $203.17. The company had a trading volume of 629,103 shares, compared to its average volume of 564,161. The company has a market cap of $17,700.78, a PE ratio of 69.11, a PEG ratio of 2.50 and a beta of 0.58. IDEXX Laboratories has a fifty-two week low of $146.09 and a fifty-two week high of $203.26. The company has a debt-to-equity ratio of -11.26, a current ratio of 0.97 and a quick ratio of 0.80.
In other news, Chairman Jonathan W. Ayers sold 36,000 shares of the company’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $179.28, for a total value of $6,454,080.00. Following the completion of the sale, the chairman now directly owns 1,077,112 shares in the company, valued at approximately $193,104,639.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jonathan W. Ayers sold 2,160 shares of the company’s stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $167.03, for a total value of $360,784.80. Following the completion of the sale, the chief executive officer now owns 1,077,112 shares of the company’s stock, valued at $179,910,017.36. The disclosure for this sale can be found here. Insiders sold a total of 91,736 shares of company stock valued at $16,193,502 over the last 90 days. 2.77% of the stock is currently owned by company insiders.
Several large investors have recently bought and sold shares of the company. Renaissance Technologies LLC increased its stake in shares of IDEXX Laboratories by 18.2% in the 4th quarter. Renaissance Technologies LLC now owns 1,879,804 shares of the company’s stock worth $293,964,000 after purchasing an additional 290,004 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of IDEXX Laboratories by 19.5% in the 4th quarter. Bank of New York Mellon Corp now owns 1,141,206 shares of the company’s stock worth $178,462,000 after purchasing an additional 185,981 shares in the last quarter. Old Mutual Global Investors UK Ltd. increased its stake in shares of IDEXX Laboratories by 19.8% in the 4th quarter. Old Mutual Global Investors UK Ltd. now owns 995,156 shares of the company’s stock worth $155,622,000 after purchasing an additional 164,777 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of IDEXX Laboratories by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 954,584 shares of the company’s stock worth $148,977,000 after purchasing an additional 16,313 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in shares of IDEXX Laboratories by 32.3% in the 4th quarter. American Century Companies Inc. now owns 946,391 shares of the company’s stock worth $147,997,000 after purchasing an additional 231,216 shares in the last quarter. Hedge funds and other institutional investors own 86.21% of the company’s stock.
WARNING: “IDEXX Laboratories (IDXX) Upgraded to Strong-Buy by BidaskClub” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://sportsperspectives.com/2018/03/11/idexx-laboratories-idxx-upgraded-to-strong-buy-by-bidaskclub.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.